G protein-coupled receptors in cancer: Biochemical interactions and drug design

Progress in Molecular Biology and Translational Science

Volumn 115, Issue , 2013, Pages 143-173

  Audigier, Yves ^a   Picault, François Xavier ^a   Chaves Almagro, Carline ^a   Masri, Bernard ^a  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

Angiogenesis; Cancer; Drug design; G protein coupled receptor; Keywords; Oligomerization; Pharmacology; Signal transduction; Tyrosine kinase receptor

Indexed keywords

EID: 84873920829     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394587-7.00004-X     Document Type: Chapter

References (203)

1. D. Young, G. Waitches, C. Birchmeier, O. Fasano, and M. Wigler Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains Cell 45 1986 711 719
2. D. Julius, T.J. Livelli, T.M. Jessell, and R. Axel Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation Science 244 1989 1057 1062
3. J.S. Gutkind, E.A. Novotny, M.R. Brann, and K.C. Robbins Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes Proc Natl Acad Sci USA 88 1991 4703 4707
4. S. Li, S. Huang, and S.B. Peng Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression Int J Oncol 27 2005 1329 1339
5. M.J. Marinissen, and J.S. Gutkind G-protein-coupled receptors and signaling networks: emerging paradigms Trends Pharmacol Sci 22 2001 368 376
6. S. Cotecchia, S. Exum, M.G. Caron, and R.J. Lefkowitz Regions of the alpha 1-Adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function Proc Natl Acad Sci USA 87 1990 2896 2900
7. L.F. Allen, R.J. Lefkowitz, M.G. Caron, and S. Cotecchia G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-Adrenergic receptor enhances mitogenesis and tumorigenicity Proc Natl Acad Sci USA 88 1991 11354 11358
8. J. Gromoll, M. Simoni, and E. Nieschlag An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man J Clin Endocrinol Metab 81 1996 1367 1370
9. V.R. Rao, G.B. Cohen, and D.D. Oprian Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness Nature 367 1994 639 642
10. E. Schipani, K. Kruse, and H. Juppner A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia Science 268 1995 98 100
11. A. Shenker, L. Laue, S. Kosugi, J.J. Merendino Jr., T. Minegishi, and G.B. Cutler Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty Nature 365 1993 652 654
12. J. Parma, L. Duprez, J. Van Sande, P. Cochaux, C. Gervy, and J. Mockel Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas Nature 365 1993 649 651
13. A. Sodhi, S. Montaner, and J.S. Gutkind Viral hijacking of G-protein-coupled-receptor signalling networks Nat Rev Mol Cell Biol 5 2004 998 1012
14. H.F. Vischer, J.W. Hulshof, I.J. de Esch, M.J. Smit, and R. Leurs Virus-encoded G-protein-coupled receptors: constitutively active (dys)regulators of cell function and their potential as drug target Ernst Schering foundation symposium proceedings 2006 187 209
15. R. Lappano, and M. Maggiolini G protein-coupled receptors: novel targets for drug discovery in cancer Nat Rev Drug Discov 10 2011 47 60
16. H.J. Lee, B. Wall, and S. Chen G-protein-coupled receptors and melanoma Pigment Cell Melanoma Res 21 2008 415 428
17. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
18. D.E. Richard, V. Vouret-Craviari, and J. Pouyssegur Angiogenesis and G-protein-coupled receptors: signals that bridge the gap Oncogene 20 2001 1556 1562
19. A. Ben-Baruch Organ selectivity in metastasis: regulation by chemokines and their receptors Clin Exp Metastasis 25 2008 345 356
20. N. Dhanasekaran, L.E. Heasley, and G.L. Johnson G protein-coupled receptor systems involved in cell growth and oncogenesis Endocr Rev 16 1995 259 270
21. C.A. Landis, S.B. Masters, A. Spada, A.M. Pace, H.R. Bourne, and L. Vallar GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours Nature 340 1989 692 696
22. M.P. Graziano, and A.G. Gilman Synthesis in Escherichia coli of GTPase-deficient mutants of Gs alpha J Biol Chem 264 1989 15475 15482
23. E. Clementi, N. Malgaretti, J. Meldolesi, and R. Taramelli A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumours Oncogene 5 1990 1059 1061
24. C. O'Sullivan, C.M. Barton, S.L. Staddon, C.L. Brown, and N.R. Lemoine Activating point mutations of the gsp oncogene in human thyroid adenomas Mol Carcinog 4 1991 345 349
25. H.G. Suarez, J.A. du Villard, B. Caillou, M. Schlumberger, C. Parmentier, and R. Monier gsp mutations in human thyroid tumours Oncogene 6 1991 677 679
26. L.S. Weinstein, A. Shenker, P.V. Gejman, M.J. Merino, E. Friedman, and A.M. Spiegel Activating mutations of the stimulatory G protein in the McCune-Albright syndrome N Engl J Med 325 1991 1688 1695
27. J. Lyons, C.A. Landis, G. Harsh, L. Vallar, K. Grunewald, and H. Feichtinger Two G protein oncogenes in human endocrine tumors Science 249 1990 655 659
28. D.Q. Wu, C.H. Lee, S.G. Rhee, and M.I. Simon Activation of phospholipase C by the alpha subunits of the Gq and G11 proteins in transfected Cos-7 cells J Biol Chem 267 1992 1811 1817
29. N.X. Qian, M. Russell, A.M. Buhl, and G.L. Johnson Expression of GTPase-deficient G alpha 16 inhibits Swiss 3T3 cell growth J Biol Chem 269 1994 17417 17423
30. M. De Vivo, J. Chen, J. Codina, and R. Iyengar Enhanced phospholipase C stimulation and transformation in NIH-3T3 cells expressing Q209LGq-Alpha- subunits J Biol Chem 267 1992 18263 18266
31. G. Kalinec, A.J. Nazarali, S. Hermouet, N. Xu, and J.S. Gutkind Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells Mol Cell Biol 12 1992 4687 4693
32. H. Jiang, D. Wu, and M.I. Simon The transforming activity of activated G alpha 12 FEBS Lett 330 1993 319 322
33. M.V. Vara Prasad, S.K. Shore, and N. Dhanasekaran Activated mutant of G alpha 13 induces Egr-1, c-fos, and transformation in NIH 3T3 cells Oncogene 9 1994 2425 2429
34. N. Xu, L. Bradley, I. Ambdukar, and J.S. Gutkind A mutant alpha subunit of G12 potentiates the eicosanoid pathway and is highly oncogenic in NIH 3T3 cells Proc Natl Acad Sci USA 90 1993 6741 6745
35. A.M. Chan, T.P. Fleming, E.S. McGovern, M. Chedid, T. Miki, and S.A. Aaronson Expression cDNA cloning of a transforming gene encoding the wild-type G alpha 12 gene product Mol Cell Biol 13 1993 762 768
36. D. Bian, C. Mahanivong, J. Yu, S.M. Frisch, Z.K. Pan, and R.D. Ye The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration Oncogene 25 2006 2234 2244
37. X. Xu, and G.D. Prestwich Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model Cancer 116 2010 1739 1750
38. S. Even-Ram, B. Uziely, P. Cohen, S. Grisaru-Granovsky, M. Maoz, and Y. Ginzburg Thrombin receptor overexpression in malignant and physiological invasion processes Nat Med 4 1998 909 914
39. T.E. Meigs, M. Fedor-Chaiken, D.D. Kaplan, R. Brackenbury, and P.J. Casey Galpha12 and Galpha13 negatively regulate the adhesive functions of cadherin J Biol Chem 277 2002 24594 24600
40. D.E. Richard, E. Berra, and J. Pouyssegur Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells J Biol Chem 275 2000 26765 26771
41. B. Williams, A.Q. Baker, B. Gallacher, and D. Lodwick Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells Hypertension 25 1995 913 917
42. R.M. Drenan, C.A. Doupnik, M.P. Boyle, L.J. Muglia, J.E. Huettner, and M.E. Linder Palmitoylation regulates plasma membrane-nuclear shuttling of R7BP, a novel membrane anchor for the RGS7 family J Cell Biol 169 2005 623 633
43. T. Kino, A. Tiulpakov, T. Ichijo, L. Chheng, T. Kozasa, and G.P. Chrousos G protein beta interacts with the glucocorticoid receptor and suppresses its transcriptional activity in the nucleus J Cell Biol 169 2005 885 896
44. J.G. Park, A. Muise, G.P. He, S.W. Kim, and H.S. Ro Transcriptional regulation by the gamma5 subunit of a heterotrimeric G protein during adipogenesis EMBO J 18 1999 4004 4012
45. B.D. Spiegelberg, and H.E. Hamm G betagamma binds histone deacetylase 5 (HDAC5) and inhibits its transcriptional co-repression activity J Biol Chem 280 2005 41769 41776
46. J.H. Hurst, and S.B. Hooks Regulator of G-protein signaling (RGS) proteins in cancer biology Biochem Pharmacol 78 2009 1289 1297
47. M. Manzur, J. Hamzah, and R. Ganss Modulation of g protein signaling normalizes tumor vessels Cancer Res 69 2009 396 399
48. R. Nusse Wnt signaling in disease and in development Cell Res 15 2005 28 32
49. G. Joslyn, M. Carlson, A. Thliveris, H. Albertsen, L. Gelbert, and W. Samowitz Identification of deletion mutations and three new genes at the familial polyposis locus Cell 66 1991 601 613
50. I. Nishisho, Y. Nakamura, Y. Miyoshi, Y. Miki, H. Ando, and A. Horii Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients Science 253 1991 665 669
51. J. Behrens, and B. Lustig The Wnt connection to tumorigenesis Int J Dev Biol 48 2004 477 487
52. I. Revet, G. Huizenga, J. Koster, R. Volckmann, P. van Sluis, and R. Versteeg MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3 Cancer Lett 289 2010 195 207
53. K.M. Cadigan, and Y.I. Liu Wnt signaling: complexity at the surface J Cell Sci 119 2006 395 402
54. E. Vincan, P.K. Darcy, C.A. Farrelly, M.C. Faux, T. Brabletz, and R.G. Ramsay Frizzled-7 dictates three-dimensional organization of colorectal cancer cell carcinoids Oncogene 26 2007 2340 2352
55. V.F. Taelman, R. Dobrowolski, J.L. Plouhinec, L.C. Fuentealba, P.P. Vorwald, and I. Gumper Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes Cell 143 2010 1136 1148
56. K. Hoffmeyer, A. Raggioli, S. Rudloff, R. Anton, A. Hierholzer, and I. Del Valle Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells Science 336 2012 1549 1554
57. M. Kasper, G. Regl, A.M. Frischauf, and F. Aberger GLI transcription factors: mediators of oncogenic Hedgehog signalling Eur J Cancer 42 2006 437 445
58. Y. Katoh, and M. Katoh Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation Curr Mol Med 9 2009 873 886
59. J. Jiang, and C.C. Hui Hedgehog signaling in development and cancer Dev Cell 15 2008 801 812
60. L. Lum, and P.A. Beachy The Hedgehog response network: sensors, switches, and routers Science 304 2004 1755 1759
61. M. Stacey, H.H. Lin, S. Gordon, and A.J. McKnight LNB-TM7, a group of seven-transmembrane proteins related to family-B G-protein-coupled receptors Trends Biochem Sci 25 2000 284 289
62. S. Yona, H.H. Lin, W.O. Siu, S. Gordon, and M. Stacey Adhesion-GPCRs: emerging roles for novel receptors Trends Biochem Sci 33 2008 491 500
63. G.W. Chang, M. Stacey, M.J. Kwakkenbos, J. Hamann, S. Gordon, and H.H. Lin Proteolytic cleavage of the EMR2 receptor requires both the extracellular stalk and the GPS motif FEBS Lett 547 2003 145 150
64. V. Krasnoperov, Y. Lu, L. Buryanovsky, T.A. Neubert, K. Ichtchenko, and A.G. Petrenko Post-translational proteolytic processing of the calcium-independent receptor of alpha-latrotoxin (CIRL), a natural chimera of the cell adhesion protein and the G protein-coupled receptor. Role of the G protein-coupled receptor proteolysis site (GPS) motif J Biol Chem 277 2002 46518 46526
65. H.H. Lin, G.W. Chang, J.Q. Davies, M. Stacey, J. Harris, and S. Gordon Autocatalytic cleavage of the EMR2 receptor occurs at a conserved G protein-coupled receptor proteolytic site motif J Biol Chem 279 2004 31823 31832
66. G. Aust, M. Steinert, A. Schutz, C. Boltze, M. Wahlbuhl, and J. Hamann CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas Am J Clin Pathol 118 2002 699 707
67. T. Wang, Y. Ward, L. Tian, R. Lake, L. Guedez, and W.G. Stetler-Stevenson CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells Blood 105 2005 2836 2844
68. T. Mustafa, A. Eckert, T. Klonisch, A. Kehlen, P. Maurer, and M. Klintschar Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas Cancer Epidemiol Biomarkers Prev 14 2005 108 119
69. Y. Ward, R. Lake, J.J. Yin, C.D. Heger, M. Raffeld, and P.K. Goldsmith LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells Cancer Res 71 2011 7301 7311
70. H. Nishimori, T. Shiratsuchi, T. Urano, Y. Kimura, K. Kiyono, and K. Tatsumi A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis Oncogene 15 1997 2145 2150
71. Y. Fukushima, Y. Oshika, T. Tsuchida, T. Tokunaga, H. Hatanaka, and H. Kijima Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer Int J Oncol 13 1998 967 970
72. L. Yang, G. Chen, S. Mohanty, G. Scott, F. Fazal, and A. Rahman GPR56 Regulates VEGF production and angiogenesis during melanoma progression Cancer Res 71 2011 5558 5568
73. S. Shashidhar, G. Lorente, U. Nagavarapu, A. Nelson, J. Kuo, and J. Cummins GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion Oncogene 24 2005 1673 1682
74. A.M. Lum, B.B. Wang, G.B. Beck-Engeser, L. Li, N. Channa, and M. Wabl Orphan receptor GPR110, an oncogene overexpressed in lung and prostate cancer BMC Cancer 10 2010 40
75. E.B. Carson-Walter, D.N. Watkins, A. Nanda, B. Vogelstein, K.W. Kinzler, and B. St Croix Cell surface tumor endothelial markers are conserved in mice and humans Cancer Res 61 2001 6649 6655
76. Y. Saito, and B.C. Berk Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors J Mol Cell Cardiol 33 2001 3 7
77. P. Crespo, N. Xu, W.F. Simonds, and J.S. Gutkind Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits Nature 369 1994 418 420
78. M. Faure, T.A. Voyno-Yasenetskaya, and H.R. Bourne cAMP and beta gamma subunits of heterotrimeric G proteins stimulate the mitogen-Activated protein kinase pathway in COS-7 cells J Biol Chem 269 1994 7851 7854
79. W.J. Koch, B.E. Hawes, L.F. Allen, and R.J. Lefkowitz Direct evidence that Gi-coupled receptor stimulation of mitogen-Activated protein kinase is mediated by G beta gamma activation of p21ras Proc Natl Acad Sci USA 91 1994 12706 12710
80. A.M. Buhl, N. Avdi, G.S. Worthen, and G.L. Johnson Mapping of the C5a receptor signal transduction network in human neutrophils Proc Natl Acad Sci USA 91 1994 9190 9194
81. G.S. Worthen, N. Avdi, A.M. Buhl, N. Suzuki, and G.L. Johnson FMLP activates Ras and Raf in human neutrophils. Potential role in activation of MAP kinase J Clin Invest 94 1994 815 823
82. J. Alblas, E.J. van Corven, P.L. Hordijk, G. Milligan, and W.H. Moolenaar Gi-mediated activation of the p21ras-mitogen-Activated protein kinase pathway by alpha 2-Adrenergic receptors expressed in fibroblasts J Biol Chem 268 1993 22235 22238
83. S. Winitz, M. Russell, N.X. Qian, A. Gardner, L. Dwyer, and G.L. Johnson Involvement of Ras and Raf in the Gi-coupled acetylcholine muscarinic m2 receptor activation of mitogen-Activated protein (MAP) kinase kinase and MAP kinase J Biol Chem 268 1993 19196 19199
84. L.R. Howe, and C.J. Marshall Lysophosphatidic acid stimulates mitogen-Activated protein kinase activation via a G-protein-coupled pathway requiring p21ras and p74raf-1 J Biol Chem 268 1993 20717 20720
85. E.J. van Corven, P.L. Hordijk, R.H. Medema, J.L. Bos, and W.H. Moolenaar Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts Proc Natl Acad Sci USA 90 1993 1257 1261
86. J. Chen, and R. Iyengar Suppression of Ras-induced transformation of NIH 3T3 cells by activated G alpha s Science 263 1994 1278 1281
87. B.E. Hawes, T. van Biesen, W.J. Koch, L.M. Luttrell, and R.J. Lefkowitz Distinct pathways of Gi- and Gq-mediated mitogen-Activated protein kinase activation J Biol Chem 270 1995 17148 17153
88. T. van Biesen, B.E. Hawes, D.K. Luttrell, K.M. Krueger, K. Touhara, and E. Porfiri Receptor-tyrosine-kinase- and G beta gamma-mediated MAP kinase activation by a common signalling pathway Nature 376 1995 781 784
89. H. Daub, F.U. Weiss, C. Wallasch, and A. Ullrich Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors Nature 379 1996 557 560
90. N.E. Bhola, and J.R. Grandis Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer Front Biosci 13 2008 1857 1865
91. N. Prenzel, E. Zwick, H. Daub, M. Leserer, R. Abraham, and C. Wallasch EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF Nature 402 1999 884 888
92. S. Eguchi, K. Numaguchi, H. Iwasaki, T. Matsumoto, T. Yamakawa, and H. Utsunomiya Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-Activated protein kinase activation in vascular smooth muscle cells J Biol Chem 273 1998 8890 8896
93. L.Q. Fuentes, C.E. Reyes, J.M. Sarmiento, C.I. Villanueva, C.D. Figueroa, and J. Navarro Vasopressin up-regulates the expression of growth-related immediate-early genes via two distinct EGF receptor transactivation pathways Cell Signal 20 2008 1642 1650
94. S. Maudsley, K.L. Pierce, A.M. Zamah, W.E. Miller, S. Ahn, and Y. Daaka The beta(2)-Adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor J Biol Chem 275 2000 9572 9580
95. D.G. Tilley, I.M. Kim, P.A. Patel, J.D. Violin, and H.A. Rockman beta-Arrestin mediates beta1-Adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling J Biol Chem 284 2009 20375 20386
96. M. Zajac, J. Law, D.D. Cvetkovic, M. Pampillo, L. McColl, and C. Pape GPR54 (KISS1R) transactivates EGFR to promote breast cancer cell invasiveness PLoS One 6 2011 e21599
97. B. Schafer, A. Gschwind, and A. Ullrich Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion Oncogene 23 2004 991 999
98. E.J. Filardo, J.A. Quinn, K.I. Bland, and A.R. Frackelton Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-Activation of the epidermal growth factor receptor through release of HB-EGF Mol Endocrinol 14 2000 1649 1660
99. L. Albanito, A. Madeo, R. Lappano, A. Vivacqua, V. Rago, and A. Carpino G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells Cancer Res 67 2007 1859 1866
100. Q.K. Chan, H.M. Lam, C.F. Ng, A.Y. Lee, E.S. Chan, and H.K. Ng Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest Cell Death Differ 17 2010 1511 1523
101. D.P. Pandey, R. Lappano, L. Albanito, A. Madeo, M. Maggiolini, and D. Picard Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF EMBO J 28 2009 523 532
102. A. Vivacqua, D. Bonofiglio, A.G. Recchia, A.M. Musti, D. Picard, and S. Ando The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells Mol Endocrinol 20 2006 631 646
103. M.S. Simonson, Y. Wang, and W.H. Herman Nuclear signaling by endothelin-1 requires Src protein-tyrosine kinases J Biol Chem 271 1996 77 82
104. S. Lev, H. Moreno, R. Martinez, P. Canoll, E. Peles, and J.M. Musacchio Protein tyrosine kinase PYK2 involved in Ca(2 +)-induced regulation of ion channel and MAP kinase functions Nature 376 1995 737 745
105. I. Dikic, G. Tokiwa, S. Lev, S.A. Courtneidge, and J. Schlessinger A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation Nature 383 1996 547 550
106. J. Andreev, M.L. Galisteo, O. Kranenburg, S.K. Logan, E.S. Chiu, and M. Okigaki Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-Activated protein (MAP) kinase signaling cascade J Biol Chem 276 2001 20130 20135
107. W. Tsai, A.D. Morielli, and E.G. Peralta The m1 muscarinic acetylcholine receptor transactivates the EGF receptor to modulate ion channel activity EMBO J 16 1997 4597 4605
108. S.J. Keely, J.M. Uribe, and K.E. Barrett Carbachol stimulates transactivation of epidermal growth factor receptor and mitogen-Activated protein kinase in T84 cells. Implications for carbachol-stimulated chloride secretion J Biol Chem 273 1998 27111 27117
109. D. Wang, X. Yu, R.A. Cohen, and P. Brecher Distinct effects of N-Acetylcysteine and nitric oxide on angiotensin II-induced epidermal growth factor receptor phosphorylation and intracellular Ca(2 +) levels J Biol Chem 275 2000 12223 12230
110. S. Heeneman, J. Haendeler, Y. Saito, M. Ishida, and B.C. Berk Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc J Biol Chem 275 2000 15926 15932
111. D.A. Linseman, C.W. Benjamin, and D.A. Jones Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells J Biol Chem 270 1995 12563 12568
112. U.F. Mondorf, H. Geiger, M. Herrero, S. Zeuzem, and A. Piiper Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells FEBS Lett 472 2000 129 132
113. J. Abe, J. Deguchi, T. Matsumoto, N. Takuwa, M. Noda, and M. Ohno Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries: a link between angiotensin II and intimal thickening Circulation 96 1997 1906 1913
114. F. Vacca, A. Bagnato, K.J. Catt, and R. Tecce Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells Cancer Res 60 2000 5310 5317
115. A. Madeo, and M. Maggiolini Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-Associated fibroblasts Cancer Res 70 2010 6036 6046
116. U. Kumar Cross-talk and modulation of signaling between somatostatin and growth factor receptors Endocrine 40 2011 168 180
117. H.L. Watt, G.D. Kharmate, and U. Kumar Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells Cell Signal 21 2009 428 439
118. G. Kharmate, P.S. Rajput, H.L. Watt, R.K. Somvanshi, N. Chaudhari, and X. Qiu Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling Biochim Biophys Acta 1813 2011 1172 1189
119. G. Kharmate, P.S. Rajput, H.L. Watt, R.K. Somvanshi, N. Chaudhari, and X. Qiu Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signaling pathways Endocrinology 152 2011 931 945
120. K. Berns, H.M. Horlings, B.T. Hennessy, M. Madiredjo, E.M. Hijmans, and K. Beelen A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 2007 395 402
121. N. Delcourt, J. Bockaert, and P. Marin GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation Trends Pharmacol Sci 28 2007 602 607
122. E. Mira, R.A. Lacalle, M.A. Gonzalez, C. Gomez-Mouton, J.L. Abad, and A. Bernad A role for chemokine receptor transactivation in growth factor signaling EMBO Rep 2 2001 151 156
123. J.P. Hobson, H.M. Rosenfeldt, L.S. Barak, A. Olivera, S. Poulton, and M.G. Caron Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility Science 291 2001 1800 1803
124. C. Akekawatchai, J.D. Holland, M. Kochetkova, J.C. Wallace, and S.R. McColl Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells J Biol Chem 280 2005 39701 39708
125. L.M. Luttrell, T. van Biesen, B.E. Hawes, W.J. Koch, K. Touhara, and R.J. Lefkowitz G beta gamma subunits mediate mitogen-Activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor J Biol Chem 270 1995 16495 16498
126. F. Alderton, S. Rakhit, K.C. Kong, T. Palmer, B. Sambi, and S. Pyne Tethering of the platelet-derived growth factor beta receptor to G-protein-coupled receptors. A novel platform for integrative signaling by these receptor classes in mammalian cells J Biol Chem 276 2001 28578 28585
127. M.L. Halls Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation Br J Pharmacol 165 2012 1644 1658
128. W. Sun, and J. Yang Molecular basis of lysophosphatidic acid-induced NF-kappaB activation Cell Signal 22 2010 1799 1803
129. J.S. Lyssand, M.C. DeFino, X.B. Tang, A.L. Hertz, D.B. Feller, and J.L. Wacker Blood pressure is regulated by an alpha1D-Adrenergic receptor/dystrophin signalosome J Biol Chem 283 2008 18792 18800
130. M.L. Halls, and D.M. Cooper Sub-picomolar relaxin signalling by a pre-Assembled RXFP1, AKAP79, AC2, beta-Arrestin 2, PDE4D3 complex EMBO J 29 2010 2772 2787
131. T. Klonisch, J. Bialek, Y. Radestock, C. Hoang-Vu, and S. Hombach-Klonisch Relaxin-like ligand-receptor systems are autocrine/paracrine effectors in tumor cells and modulate cancer progression and tissue invasiveness Adv Exp Med Biol 612 2007 104 118
132. J. Mendelsohn Blockade of receptors for growth factors: an anticancer therapy - the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture Clin Cancer Res 6 2000 747 753
133. T.W. Moody Peptide hormones and lung cancer Panminerva Med 48 2006 19 26
134. E. Rozengurt Neuropeptides as growth factors for normal and cancerous cells Trends Endocrinol Metab 13 2002 128 134
135. D.C. Chan, M. Geraci, and P.A. Bunn Jr. Anti-growth factor therapy for lung cancer Drug Resist Update 1 1998 377 388
136. F. Cuttitta, D.N. Carney, J. Mulshine, T.W. Moody, J. Fedorko, and A. Fischler Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer Nature 316 1985 823 826
137. A.N. Corps, L.H. Rees, and K.D. Brown A peptide that inhibits the mitogenic stimulation of Swiss 3T3 cells by bombesin or vasopressin Biochem J 231 1985 781 784
138. R.T. Jensen, S.W. Jones, K. Folkers, and J.D. Gardner A synthetic peptide that is a bombesin receptor antagonist Nature 309 1984 61 63
139. K. Tsou, S.X. Wu, Y.A. Lu, and E.L. Way Block of the hyoscine-resistant opiate withdrawal contracture of ileum by a new substance P antagonist [D-Arg1, D-Phe5, D- Trp7,9, Leu 11]substance P Eur J Pharmacol 110 1985 155 156
140. P.J. Woll, and E. Rozengurt [D-Arg1, D-Phe5, D-Trp7,9, Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro Proc Natl Acad Sci USA 85 1988 1859 1863
141. P.J. Woll, and E. Rozengurt Two classes of antagonist interact with receptors for the mitogenic neuropeptides bombesin, bradykinin, and vasopressin Growth Factors 1 1988 75 83
142. X.H. Gu, D.J. Casley, and W.G. Nayler The inhibitory effect of [D-Arg1, D-Phe, D-Try7,9, Leu11]substance P on endothelin-1 binding sites in rat cardiac membranes Biochem Biophys Res Commun 179 1991 130 133
143. M.B. Jarpe, C. Knall, F.M. Mitchell, A.M. Buhl, E. Duzic, and G.L. Johnson [D-Arg1, D-Phe5, D-Trp7,9, Leu11]substance P acts as a biased agonist toward neuropeptide and chemokine receptors J Biol Chem 273 1998 3097 3104
144. J.G. Reeve, and N.M. Bleehen [D-Arg1, D-Phe5, D-Trp7,9, Leu11]substance P induces apoptosis in lung cancer cell lines in vitro Biochem Biophys Res Commun 199 1994 1313 1319
145. M.J. Seckl, T. Higgins, F. Widmer, and E. Rozengurt [D-Arg1, D-Trp5,7,9, Leu11]substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells Cancer Res 57 1997 51 54
146. T. Sethi, S. Langdon, J. Smyth, and E. Rozengurt Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo Cancer Res 52 1992 2737s 2742s
147. P.J. Woll, and E. Rozengurt A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro Cancer Res 50 1990 3968 3973
148. S. Langdon, T. Sethi, A. Ritchie, M. Muir, J. Smyth, and E. Rozengurt Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo Cancer Res 52 1992 4554 4557
149. A.C. MacKinnon, R.A. Armstrong, C.M. Waters, J. Cummings, J.F. Smyth, and C. Haslett [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism Br J Cancer 80 1999 1026 1034
150. J.M. Stewart Bradykinin antagonists as anti-cancer agents Curr Pharm Des 9 2003 2036 2042
151. S. Guha, G. Eibl, K. Kisfalvi, R.S. Fan, M. Burdick, and H. Reber Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1, D-Trp5,7,9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer Cancer Res 65 2005 2738 2745
152. D. Chan, L. Gera, J. Stewart, B. Helfrich, M. Verella-Garcia, and G. Johnson Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism Proc Natl Acad Sci USA 99 2002 4608 4613
153. D.C. Chan, L. Gera, J.M. Stewart, B. Helfrich, T.L. Zhao, and W.Y. Feng Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents Clin Cancer Res 8 2002 1280 1287
154. J.M. Stewart, L. Gera, D.C. Chan, P.A. Bunn Jr., E.J. York, and V. Simkeviciene Bradykinin-related compounds as new drugs for cancer and inflammation Can J Physiol Pharmacol 80 2002 275 280
155. M.D. Culler Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors Horm Metab Res 43 2011 854 857
156. L.J. Hofland, and S.W. Lamberts The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev 24 2003 28 47
157. C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, and G. Weckbecker SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur J Endocrinol 146 2002 707 716
158. A. Saveanu, G. Gunz, H. Dufour, P. Caron, F. Fina, and L. Ouafik Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas J Clin Endocrinol Metab 86 2001 140 145
159. M.D. Culler, K. Oberg, R. Arnold, E.P. Krenning, I. Sevilla, and J.A. Diaz Somatostatin analogs for the treatment of neuroendocrine tumors Cancer Metastasis Rev 30 Suppl. 1 2011 9 17
160. M.E. Molitch, R.L. Elton, R.E. Blackwell, B. Caldwell, R.J. Chang, and R. Jaffe Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study J Clin Endocrinol Metab 60 1985 698 705
161. A. Colao, A. Di Sarno, F. Sarnacchiaro, D. Ferone, G. Di Renzo, and B. Merola Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment J Clin Endocrinol Metab 82 1997 876 883
162. R. Pivonello, D. Ferone, W.W. de Herder, J.M. Kros, M.L. De Caro, and M. Arvigo Dopamine receptor expression and function in corticotroph pituitary tumors J Clin Endocrinol Metab 89 2004 2452 2462
163. A.K. Flogstad, J. Halse, P. Grass, E. Abisch, O. Djoseland, and K. Kutz A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly J Clin Endocrinol Metab 79 1994 461 465
164. G. Minniti, M.L. Jaffrain-Rea, R. Baldelli, E. Ferretti, B. Caracciolo, and A. Bultrini Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients Clin Ter 148 1997 601 607
165. M. Rocheville, D.C. Lange, U. Kumar, S.C. Patel, R.C. Patel, and Y.C. Patel Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity Science 288 2000 154 157
166. A. Baragli, H. Alturaihi, H.L. Watt, A. Abdallah, and U. Kumar Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis Cell Signal 19 2007 2304 2316
167. C. de Bruin, R.A. Feelders, S.W. Lamberts, and L.J. Hofland Somatostatin and dopamine receptors as targets for medical treatment of Cushing's syndrome Rev Endocr Metab Disord 10 2009 91 102
168. A. Saveanu, and P. Jaquet Somatostatin-dopamine ligands in the treatment of pituitary adenomas Rev Endocr Metab Disord 10 2009 83 90
169. D. Ferone, M. Arvigo, C. Semino, P. Jaquet, A. Saveanu, and J.E. Taylor Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation Am J Physiol Endocrinol Metab 289 2005 E1044 E1050
170. S.G. Ren, S. Kim, J. Taylor, J. Dong, J.P. Moreau, and M.D. Culler Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand J Clin Endocrinol Metab 88 2003 5414 5421
171. A. Saveanu, E. Lavaque, G. Gunz, A. Barlier, S. Kim, and J.E. Taylor Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells J Clin Endocrinol Metab 87 2002 5545 5552
172. P. Jaquet, G. Gunz, A. Saveanu, A. Barlier, H. Dufour, and J. Taylor BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide J Endocrinol Invest 28 2005 21 27
173. M. Bouvier, N. Heveker, R. Jockers, S. Marullo, and G. Milligan BRET analysis of GPCR oligomerization: newer does not mean better Nat Methods 4 2007 3 4 author reply 4
174. M. Hamatake, T. Aoki, Y. Futahashi, E. Urano, N. Yamamoto, and J. Komano Ligand-independent higher-order multimerization of CXCR4, a G-protein-coupled chemokine receptor involved in targeted metastasis Cancer Sci 100 2009 95 102
175. A. Salahpour, and B. Masri Experimental challenge to a 'rigorous' BRET analysis of GPCR oligomerization Nat Methods 4 2007 599 600 author reply 601
176. L.M. Munoz, P. Lucas, B.L. Holgado, R. Barroso, B. Vega, and J.M. Rodriguez-Frade Receptor oligomerization: a pivotal mechanism for regulating chemokine function Pharmacol Ther 131 2011 351 358
177. L.D. Bennett, J.M. Fox, and N. Signoret Mechanisms regulating chemokine receptor activity Immunology 134 2011 246 256
178. G.J. Babcock, M. Farzan, and J. Sodroski Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor J Biol Chem 278 2003 3378 3385
179. J. Wang, L. He, C.A. Combs, G. Roderiquez, and M.A. Norcross Dimerization of CXCR4 in living malignant cells: control of cell migration by a synthetic peptide that reduces homologous CXCR4 interactions Mol Cancer Ther 5 2006 2474 2483
180. A. Muller, B. Homey, H. Soto, N. Ge, D. Catron, and M.E. Buchanan Involvement of chemokine receptors in breast cancer metastasis Nature 410 2001 50 56
181. L. Covic, A.L. Gresser, J. Talavera, S. Swift, and A. Kuliopulos Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides Proc Natl Acad Sci USA 99 2002 643 648
182. P. Dimond, K. Carlson, M. Bouvier, C. Gerard, L. Xu, and L. Covic G protein-coupled receptor modulation with pepducins: moving closer to the clinic Ann N Y Acad Sci 1226 2011 34 49
183. K. O'Callaghan, A. Kuliopulos, and L. Covic Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development J Biol Chem 287 2012 12787 12796
184. L.M. Sevigny, P. Zhang, A. Bohm, K. Lazarides, G. Perides, and L. Covic Interdicting protease-Activated receptor-2-driven inflammation with cell-penetrating pepducins Proc Natl Acad Sci USA 108 2011 8491 8496
185. R.J. Edwards, N. Moran, M. Devocelle, A. Kiernan, G. Meade, and W. Signac Bioinformatic discovery of novel bioactive peptides Nat Chem Biol 3 2007 108 112
186. B. Tchernychev, Y. Ren, P. Sachdev, J.M. Janz, L. Haggis, and A. O'Shea Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells Proc Natl Acad Sci USA 107 2010 22255 22259
187. L. Covic, M. Misra, J. Badar, C. Singh, and A. Kuliopulos Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation Nat Med 8 2002 1161 1165
188. N.C. Kaneider, A. Agarwal, A.J. Leger, and A. Kuliopulos Reversing systemic inflammatory response syndrome with chemokine receptor pepducins Nat Med 11 2005 661 665
189. S.L. Tressel, G. Koukos, B. Tchernychev, S.L. Jacques, L. Covic, and A. Kuliopulos Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models Methods Mol Biol 683 2011 259 275
190. R.T. Dorsam, and J.S. Gutkind G-protein-coupled receptors and cancer Nat Rev Cancer 7 2007 79 94
191. C.B. Martin, G.M. Mahon, M.B. Klinger, R.J. Kay, M. Symons, and C.J. Der The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways Oncogene 20 2001 1953 1963
192. A. Agarwal, L. Covic, L.M. Sevigny, N.C. Kaneider, K. Lazarides, and G. Azabdaftari Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer Mol Cancer Ther 7 2008 2746 2757
193. A. Agarwal, S.L. Tressel, R. Kaimal, M. Balla, F.H. Lam, and L. Covic Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy Cancer Res 70 2010 5880 5890
194. A. Boire, L. Covic, A. Agarwal, S. Jacques, S. Sherifi, and A. Kuliopulos PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells Cell 120 2005 303 313
195. P. Ghio, S. Cappia, G. Selvaggi, S. Novello, P. Lausi, and G. Zecchina Prognostic role of protease-Activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer Clin Lung Cancer 7 2006 395 400
196. E. Yang, A. Boire, A. Agarwal, N. Nguyen, K. O'Callaghan, and P. Tu Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis Cancer Res 69 2009 6223 6231
197. J. Cisowski, K. O'Callaghan, A. Kuliopulos, J. Yang, N. Nguyen, and Q. Deng Targeting protease-Activated receptor-1 with cell-penetrating pepducins in lung cancer Am J Pathol 179 2011 513 523
198. A. Jikuhara, M. Yoshii, H. Iwagaki, S. Mori, M. Nishibori, and N. Tanaka MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-Activated receptor 2 Life Sci 73 2003 2817 2829
199. R. Kaufmann, C. Oettel, A. Horn, K.J. Halbhuber, A. Eitner, and R. Krieg Met receptor tyrosine kinase transactivation is involved in proteinase-Activated receptor-2-mediated hepatocellular carcinoma cell invasion Carcinogenesis 30 2009 1487 1496
200. R. Shimamoto, T. Sawada, Y. Uchima, M. Inoue, K. Kimura, and Y. Yamashita A role for protease-Activated receptor-2 in pancreatic cancer cell proliferation Int J Oncol 24 2004 1401 1406
201. D.J. Waugh, and C. Wilson The interleukin-8 pathway in cancer Clin Cancer Res 14 2008 6735 6741
202. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
203. Y. Matsuo, N. Ochi, H. Sawai, A. Yasuda, H. Takahashi, and H. Funahashi CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer Int J Cancer 124 2009 853 861